In this network meta-analysis based on 24 randomized trials and 81,405 patients, we found that 3-month DAPT followed by P2Y12 inhibitor monotherapy significantly reduced net clinical events, which was mainly due to reduced risks of major and any bleeding, without increasing the incidence of composite or separate ischemic events Moreover, the benefits of 3-month DAPT (P2Y12 inhibitor) were more evident for male patients with ACS, young age, complex lesion, single-vessel disease, low BMI, and without diabetes. This evidence concerns the gene P2RY12 and diabetes mellitus.